Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06061042

Effect of Timed-Restricted Eating on Metabolic Health

We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin resistance.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Amsterdam UMC, location AMC

Amsterdam, North Holland, 1105AZ, Netherlands

Location status: Recruiting

Location contact

Jur Kroon, BSc

CONTACT

[email protected]

+31 683238752

Jur Kroon, BSc

SUB_INVESTIGATOR

About this study

Obesity is an alarming global health issue, with increasing prevalence. Obesity leads to a vast array of disorders, including dyslipidemia, the accumulation of intrahepatic triglycerides (IHTG), multiorgan insulin resistance and type 2 diabetes mellitus. In addition, disruption of the circadian rhythm (circadian misalignment), which is associated with irregular eating schedules, is an important risk factor for the development of obesity, IHTG and type 2 diabetes mellitus. Time restricted eating (TRE) is a form of intermittent fasting, in which the daily eating period is restricted. The beneficial effect of this type of diet might relate to adequate synchronization of food intake and fasting to the internal rhythm of the circadian tissue clocks, improving metabolic handling of nutrients and metabolic flexibility.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to provide informed consent;
  • BMI > 30kg/m^2;
  • Insulin resistance, as defined by fasting plasma insulin > 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose > 5.3 and < 7.0 mmol/L;
  • Stable weight for 3 months prior to study inclusion
  • For women, 1 year after last menstrual cycle

Exclusion criteria

  • Use of any medication, except for those related to treatment of metabolic syndrome;
  • Any medical condition interfering with study outcomes or design;
  • History of any psychiatric disorder, including eating disorders;
  • Performing shift work
  • Performing intensive sports (>3 hours/week);
  • Smoking;
  • Drugs abuse or alcohol abuse (>3 units/day);
  • Contraindication for MRI;
  • Known lactose/gluten intolerance;
  • Known soy, egg, milk or peanut allergy;
  • Childhood onset of obesity

Treatment and study plan

Early Time Restricted Eating

Behavioral

Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM

Other names: early-TRE

Late Time Restricted Eating

Behavioral

Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM

Other names: late-TRE

Primary outcomes

  1. Insulin Sensitivity

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.

Secondary outcomes

  1. Change in plasma insulin

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    Fasted and stimulated insulin (pmol/L) will be measured during MMTT

  2. Change in plasma glucose

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    Fasted and stimulated glucose (mmol/L) will be measured during MMTT

  3. Change in intrahepatic fat

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.

  4. Change in beta cell function (C-peptide)

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT

  5. Change in insulin aignaling

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)

  6. Change in glucose variability

    Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2

    In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.

  7. De novo lipogenesis

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration

  8. Immunological markers

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.

  9. Physical activity

    Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2

    Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.

  10. Functional brain activity

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).

  11. Psychological factor - Food Craving

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.

  12. Psychological factor - Eating behaviour

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.

  13. Psychological factor - Hunger scale

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.

  14. Psychological factor - Food addiction

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.

  15. Psychological factor - Impulsiveness

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.

  16. Psychological factor - Chronotype

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.

  17. Subject experience with intervention

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.

  18. Delay discounting computational task

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.

  19. Iowa gambling computational task

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

    We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.

Study contacts

Contact information is provided by the study sponsor or research team.

Jur Kroon, BSc

CONTACT

[email protected]

+31 683238752

Sarah E Siegelaar, MD PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Collaborators

  • Diabetesfonds

Registry information

Official study title

The Effect of Timed-Restricted Eating on Insulin Sensitivity, De Novo Lipogenesis and Liver Fat in Subjects With Obesity and Insulin Resistance

Acronym: TREAT

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Sep 29, 2023
Registry last updated
Sep 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.